**SUPPLEMENTARY FILE 3**

**Supplementary Table and Figures**

**Supplementary Table 1.** One-way deterministic sensitivity analysis result.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Parameter** | **Base Case ICER (QALY): $12,843** | | **Lower to Base Case ICER Range** | **Upper to Base Case ICER Range** | **Lower to Upper ICER Range** |
| **Lower ICER (QALY)** | **Upper ICER (QALY)** |
| Angiotensin II 28-day survival rate | $5,027 | $282,946 | –$7,817 | $270,102 | $277,919 |
| Benefit discount rate | $9,708 | $16,970 | –$3,136 | $4,126 | $7,262 |
| ICU and hospital ward daily cost | $11,366 | $14,321 | –$6,985 | $241,361 | $2,956 |
| Postsurvival mortality relative risk | $11,966 | $14,820 | –$878 | $1,977 | $2,855 |
| Angiotensin II drug cost (vial) | $11,934 | $13,752 | –$909 | $909 | $1,818 |
| Adverse event cost | $12,590 | $13,097 | –$254 | $254 | $507 |
| 48-hour background vasopressor cost\* | $12,772 | $12,915 | –$72 | $72 | $144 |
| Nonsurvivor resource inflation factor | $12,824 | $12,863 | –$19 | $19 | $39 |
| QOL measurement: EQ-5D (22) | $10,100 |  | –%2,743 |  |  |
| QOL measurement: QWB (21) |  | $13,145 |  | $302 |  |

\*Baseline vasopressors included norepinephrine, epinephrine, dopamine, phenylephrine, and vasopressin. All vasopressor prices were obtained from Micromedex Redbook at 2018 WAC price and weighted by market sales from January–May 2018.

ICER, incremental cost-effectiveness ratio; ICU, intensive care unit; QALY, quality-adjusted life years; QOL, quality of life; QWB, Quality of Well-Being scale.

**Supplementary Figure 1.** Model setting. LYG, life years gained; QALY, quality-adjusted life years.

A picture containing screenshot

Description automatically generated

**Supplementary Figure 2.** Threshold analysis, angiotensin II survival rate vs incremental cost-effectiveness ratio (QALY). QALY, quality-adjusted life years; WTP, willingness to pay.Survival rates in ATHOS-3 trial for angiotensin II arm and placebo arm were 54% and 46%, respectively.

A close up of a map

Description automatically generated

**Supplementary Figure 3.** Willingness-to-pay threshold analysis, angiotensin II price per vial vs ICER (QALY).\*ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years; WTP, willingness to pay. \*Current angiotensin II cost per vial (wholesale acquisition cost, 2018 USD): $1,500.

A close up of a map

Description automatically generated

**Supplementary Figure 4.** Cost-effectiveness acceptability curve with net monetary benefit. CE, cost-effectiveness; Prob., probability; QALY, quality-adjusted life years; WTP, willingness to pay.A close up of a map

Description automatically generated